Oxygen Biotherapeutics, Inc. (“OBI”) OXBT, announced today that it
has entered into a License and Supply Agreement with the Cosmetics Division of
Valor SA of Lausanne, Switzerland, for Dermacyte, a perfluorocarbon based
cosmetic product currently manufactured and distributed by Oxygen
Biotherapeutics. Per the agreement, Valor was granted the exclusive right to
sell, import, export, distribute, package, label and otherwise commercialize
Dermacyte. Valor also is authorized to sublicense the license granted under
this agreement provided that such sublicenses are consistent with the terms of
the original licensing agreement.
Per the terms of the agreement, Valor must pay OBI an annual, non-refundable
license fee as well as a royalty on all sales of Dermacyte when a specific
agreed upon sales goal is achieved.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in